Loading...

Nektar Therapeutics

NKTR•NASDAQ
Healthcare
Biotechnology
$100.35
$15.49(18.25%)
U.S. Market opens in 3h 20m

Nektar Therapeutics (NKTR) Stock Overview

Explore Nektar Therapeutics’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2B
P/E Ratio-12.39
EPS (TTM)$-9.73
ROE-3.99%
Fundamental Analysis

AI Price Forecasts

1 Month$74.55
3 Months$90.59
1 Year Target$117.53

NKTR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nektar Therapeutics (NKTR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 80.91, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $117.53.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -12.39 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
18.25%
5-Day Change
22.74%
1-Month Change
38.95%
3-Month Change
176.98%
6-Month Change
59.31%
Year-to-Date (YTD) Change
137.35%
1-Year Change
968.69%
3-Year Change
677.91%
5-Year Change
-64.43%
All-Time (Max) Change
78.40%

Contact Information

https://www.nektar.com
415 482 5300
455 Mission Bay Boulevard South, San Francisco, CA, 94158

Company Facts

61 Employees
IPO DateMay 3, 1994
CountryUS
Actively Trading

Frequently Asked Questions